Trial Enrollment Completed for Pulmonary Fibrosis Drug
Researchers have finished enrolling 104 patients to test a potential new treatment for idiopathic pulmonary fibrosis.
Updated on Sept. 21, 2026 in Diseases — General
Live Poll
Should government agencies grant special status and market exclusivity to pharmaceutical firms for rare disease drugs?
Daewoong Pharmaceutical has finished recruiting 104 patients for a global Phase 2 clinical trial of Bersiporocin, a potential treatment for idiopathic pulmonary fibrosis. The study participants are based in the United States and South Korea.
Why it matters
Idiopathic pulmonary fibrosis is a serious condition that causes lungs to harden and lose function due to abnormal collagen accumulation. Finding effective therapies is critical for managing this progressive disease and improving patient outcomes.
This Phase 2 trial enrolled 104 participants across the United States and South Korea. Patients are receiving either Bersiporocin or a placebo twice daily for 24 weeks to assess the treatment's impact.
The players
Daewoong Pharmaceutical
A global pharmaceutical company focused on developing novel treatments for conditions including respiratory diseases.
FDA
The U.S. federal agency responsible for regulating food, tobacco, and medical products to protect public health.
EMA
The European Union agency responsible for the scientific evaluation and monitoring of medicines for human use.
The details
Bersiporocin is designed to inhibit the activity of specific proteins that regulate collagen production in the body. By reducing these proteins, the drug aims to prevent the abnormal collagen accumulation that stiffens lung tissue. Patients in the study receive the candidate medication or a placebo twice daily for 24 weeks to evaluate its potential therapeutic effect.
Timeline
September 21, 2026: Enrollment completion was announced.
24 weeks: The duration of the treatment period for study participants.
2027: Planned announcement of key clinical trial indicators.
Health Landscape
This trial represents a clinical step forward in the search for targeted therapies to slow the progression of idiopathic pulmonary fibrosis. It follows the standard regulatory path supported by the FDA and EMA orphan drug designation program to incentivize research for rare conditions.
This development is currently in the experimental phase and is not yet an available clinical treatment. If you or a loved one are managing idiopathic pulmonary fibrosis, discuss emerging research and potential clinical trial eligibility with your pulmonologist.
The takeaway
Ongoing research into protein-inhibiting therapies offers potential future options for managing lung scarring. Patients interested in how new clinical developments may affect their long-term care plans should keep open a conversation with their respiratory specialists.
What happens next
Daewoong Pharmaceutical is expected to announce key indicators from the clinical trial in 2027.
Further reading
You can learn more about advancements in chronic care by visiting our Diseases — General section.
Live Poll
Should government agencies grant special status and market exclusivity to pharmaceutical firms for rare disease drugs?
